<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="146122">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01677286</url>
  </required_header>
  <id_info>
    <org_study_id>H-31546</org_study_id>
    <nct_id>NCT01677286</nct_id>
  </id_info>
  <brief_title>Safety and Effect of Doxycycline in Patients With Amyloidosis</brief_title>
  <official_title>A Phase II Study of Doxycycline in Patients With Amyloidosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boston University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boston University</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      The tetracycline antibiotic doxycycline disrupts A beta amyloid  fibrils (AB) in Alzheimer's
      disease,  transthyretin (ATTR) amyloid fibrils in familial amyloidotic polyneuropathy, and
      immunoglobulin light chain (AL) amyloid fibrils in transgenic mouse models of disease. If
      untreated, amyloid deposits impair organ function, affecting the morbidity and mortality of
      patients.

      This single-center, twelve-month, open-label, prospective, pilot phase II study aims to
      determine whether doxycycline reduces amyloid deposits and improves organ function in
      patients with systemic or localized amyloidosis.

      The investigators plan to enroll patients with measurable amyloid disease according to
      internationally-accepted diagnostic criteria. Patients must have stable organ function at
      enrollment. Eligible subjects not receiving active treatments for amyloidosis affecting
      their kidneys, heart, aerodigestive tracts, peripheral or autonomic nervous system(s),
      lungs, eyes, skin, bladder, or breasts will undergo evaluations at baseline, 6 months, and
      12 months - or more frequently as clinically indicated.

      Over 45 years experience indicates doxycycline is a safe, well tolerated antibiotic. The
      investigators will use standard grading systems to assess doxycycline response following
      twelve months of treatment.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>July 2012</start_date>
  <completion_date type="Anticipated">July 2015</completion_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Composite measures specific to the organ system affected by amyloidosis at study entry</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Amyloid nephropathy: 24 hour urine protein excretion, creatinine clearance
Amyloid cardiomyopathy: cardiac biomarkers (BNP, Troponin I), echo parameters (IVSd, longitudinal strain, diastolic indices [e/e']), ECG
Amyloid peripheral neuropathy: Neurologic Impairment Score-Lower Limb (NIS-LL), modified body mass index (mBMI)
Amyloid autonomic neuropathy: postural blood pressures, heart rate variability, mBMI
Localized amyloidosis:
airway -- PFTs, CT imaging, endoscopic visualization
gastrointestinal -- endoscopic visualization
bladder -- CT imaging, cystoscopy, urodynamics
skin -- direct measures of disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Life</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Quality of Life (SF-36)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Kumamoto neurologic score</measure>
    <time_frame>12 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Motor, sensory, autonomic measures of neuropathy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Amyloidosis</condition>
  <arm_group>
    <arm_group_label>Doxycycline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Doxycycline</intervention_name>
    <description>100mg by mouth twice daily for 1 year.</description>
    <arm_group_label>Doxycycline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 or older

          -  Biopsy-proven amyloidosis

          -  Biochemical or clinical evidence of amyloid induced end-organ dysfunction

        Exclusion Criteria:

          -  Concurrent use of other tetracyclines

          -  Ongoing active treatment for amyloidosis

          -  Pregnancy or unwillingness to use contraception by women of childbearing age

          -  Doxycycline drug allergy/hypersensitivity

          -  ECOG performance status &gt; 3

          -  NYHA class &gt; 3

          -  Renal insufficiency (estimated creatinine clearance &lt; 25 ml/min)

          -  Transaminitis (AST or ALT &gt; 5 times upper limit of normal)

          -  Diabetes mellitus or hemoglobin A1C &gt; 6.2%
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John L Berk, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Boston University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Samantha Pappin</last_name>
    <phone>617-638-4494</phone>
    <email>Samantha.Pappin@bmc.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Boston University</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02118</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>John L Berk, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Cardoso I, Merlini G, Saraiva MJ. 4'-iodo-4'-deoxydoxorubicin and tetracyclines disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR fibril disrupters. FASEB J. 2003 May;17(8):803-9.</citation>
    <PMID>12724338</PMID>
  </reference>
  <reference>
    <citation>Cardoso I, Saraiva MJ. Doxycycline disrupts transthyretin amyloid: evidence from studies in a FAP transgenic mice model. FASEB J. 2006 Feb;20(2):234-9.</citation>
    <PMID>16449795</PMID>
  </reference>
  <reference>
    <citation>Forloni G, Colombo L, Girola L, Tagliavini F, Salmona M. Anti-amyloidogenic activity of tetracyclines: studies in vitro. FEBS Lett. 2001 Jan 5;487(3):404-7.</citation>
    <PMID>11163366</PMID>
  </reference>
  <reference>
    <citation>Cardoso I, Martins D, Ribeiro T, Merlini G, Saraiva MJ. Synergy of combined Doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: studies in FAP mouse models. Journal of Translational Medicine. 2010;8:74.</citation>
  </reference>
  <verification_date>May 2013</verification_date>
  <lastchanged_date>May 12, 2013</lastchanged_date>
  <firstreceived_date>August 21, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Boston University</investigator_affiliation>
    <investigator_full_name>John L. Berk</investigator_full_name>
    <investigator_title>Clinical Director, Amyloid Treatment &amp; Research Program</investigator_title>
  </responsible_party>
  <keyword>AL Amyloidosis</keyword>
  <keyword>Primary Amyloidosis</keyword>
  <keyword>Hereditary Amyloidosis</keyword>
  <keyword>Familial Amyloidosis</keyword>
  <keyword>SSA Amyloidosis</keyword>
  <keyword>Senile Systemic Amyloidosis</keyword>
  <keyword>AA Amyloidosis</keyword>
  <keyword>Secondary Amyloidosis</keyword>
  <keyword>Localized Amyloidosis</keyword>
  <keyword>Systemic Amyloidosis</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Amyloidosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Doxycycline</mesh_term>
    <mesh_term>Doxycycline hyclate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
